Our collaborative team has made fundamental discoveries in identifying HER family members as critical mediators of resistance to cetuximab in HNSCC patients and uncovering that targeting c-Abl and Axl can aid in resensitizing patients to cetuximab therapy (Figure 2A). This evidence concerns the gene AXL and head and neck squamous cell carcinoma.